Cargando…

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrex...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Wenbo, Li, Caixia, Tang, Jun, Song, Jinlong, Li, Zixiang, Sun, Jize, Xu, Yili, Zheng, Zhaomin, Cao, Jingqin, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875237/
https://www.ncbi.nlm.nih.gov/pubmed/31819623
http://dx.doi.org/10.2147/CMAR.S217524
_version_ 1783472984709660672
author Shao, Wenbo
Li, Caixia
Tang, Jun
Song, Jinlong
Li, Zixiang
Sun, Jize
Xu, Yili
Zheng, Zhaomin
Cao, Jingqin
Zhang, Lei
author_facet Shao, Wenbo
Li, Caixia
Tang, Jun
Song, Jinlong
Li, Zixiang
Sun, Jize
Xu, Yili
Zheng, Zhaomin
Cao, Jingqin
Zhang, Lei
author_sort Shao, Wenbo
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrexed plus oxaliplatin-based TACE was performed according to the traditional method at monthly intervals and was repeated for up to 4 cycles if no disease progression or intolerable toxicity occurred. The primary efficacy endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and tumor response rate. The Cox proportional-hazards regression model was used to assess the independent prognostic factors of OS. Adverse events were also observed. RESULTS: The median OS time and PFS were 623 days (95% CI: 461, 785) and 338 days (95% CI: 302, 704), respectively. The disease control rate was 95.5% (118/123). The Cox proportional-hazards regression model indicated that age, ECOG performance status and response to TACE as independent prognostic factors of OS. No treatment-related mortality occurred within 30 days of treatment procedure. The most common complications included postembolization syndrome, liver dysfunction and hematological toxicity. Grade 3 pain, transglutaminase abnormality and thrombocytopenia were observed in 16 (13%), 15 (12.2%) and 3 (2.4%) patients, respectively. No grade 4 adverse events were observed. CONCLUSION: Raltitrexed plus oxaliplatin-based TACE led to high tumor response rate and promising PFS and OS, and was considered safe and tolerable in patients with unresectable HCC.
format Online
Article
Text
id pubmed-6875237
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68752372019-12-09 Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma Shao, Wenbo Li, Caixia Tang, Jun Song, Jinlong Li, Zixiang Sun, Jize Xu, Yili Zheng, Zhaomin Cao, Jingqin Zhang, Lei Cancer Manag Res Short Report OBJECTIVE: To evaluate the efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 123 patients with unresectable HCC were recruited into the prospective cohort study. Raltitrexed plus oxaliplatin-based TACE was performed according to the traditional method at monthly intervals and was repeated for up to 4 cycles if no disease progression or intolerable toxicity occurred. The primary efficacy endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and tumor response rate. The Cox proportional-hazards regression model was used to assess the independent prognostic factors of OS. Adverse events were also observed. RESULTS: The median OS time and PFS were 623 days (95% CI: 461, 785) and 338 days (95% CI: 302, 704), respectively. The disease control rate was 95.5% (118/123). The Cox proportional-hazards regression model indicated that age, ECOG performance status and response to TACE as independent prognostic factors of OS. No treatment-related mortality occurred within 30 days of treatment procedure. The most common complications included postembolization syndrome, liver dysfunction and hematological toxicity. Grade 3 pain, transglutaminase abnormality and thrombocytopenia were observed in 16 (13%), 15 (12.2%) and 3 (2.4%) patients, respectively. No grade 4 adverse events were observed. CONCLUSION: Raltitrexed plus oxaliplatin-based TACE led to high tumor response rate and promising PFS and OS, and was considered safe and tolerable in patients with unresectable HCC. Dove 2019-11-19 /pmc/articles/PMC6875237/ /pubmed/31819623 http://dx.doi.org/10.2147/CMAR.S217524 Text en © 2019 Shao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Shao, Wenbo
Li, Caixia
Tang, Jun
Song, Jinlong
Li, Zixiang
Sun, Jize
Xu, Yili
Zheng, Zhaomin
Cao, Jingqin
Zhang, Lei
Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title_full Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title_fullStr Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title_full_unstemmed Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title_short Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
title_sort efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875237/
https://www.ncbi.nlm.nih.gov/pubmed/31819623
http://dx.doi.org/10.2147/CMAR.S217524
work_keys_str_mv AT shaowenbo efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT licaixia efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT tangjun efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT songjinlong efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT lizixiang efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT sunjize efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT xuyili efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT zhengzhaomin efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT caojingqin efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma
AT zhanglei efficacyandsafetyofraltitrexedplusoxaliplatinbasedtransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma